dydrogesterone has been researched along with Breast Cancer in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Cassidy, S; Gursul, D; Saul, H; Vinogradova, Y | 1 |
| Cai, G; Gu, M; Li, X; Mueck, AO; Ruan, X; Wang, L; Zhao, Y | 1 |
| Brinkhuis, M; Franke, HR; Jansen, GH; Vermes, I; Wolbers, F | 1 |
| Bühling, KJ; Mueck, AO; Seeger, H | 1 |
| Jick, SS; Meier, CR; Schneider, C | 1 |
| Franke, HR; Vermes, I | 1 |
| Ciftci, Z; Franke, HR; Haanen, C; Kole, S; Vermes, I | 1 |
| Franke, HR; Vermes, I; Werner, HM | 1 |
| Berrino, F; Clavel-Chapelon, F; Fournier, A | 1 |
| Berrino, F; Boutron-Ruault, MC; Clavel-Chapelon, F; Fabre, A; Fournier, A; Mesrine, S | 1 |
| Biglia, N; Campagnoli, C; Lanza, MG; Lesca, L; Peris, C; Sismondi, P | 1 |
1 review(s) available for dydrogesterone and Breast Cancer
| Article | Year |
|---|---|
Use of dydrogesterone in hormone replacement therapy.
Topics: Breast Neoplasms; Cardiovascular Diseases; Drug Therapy, Combination; Dydrogesterone; Endometrial Hyperplasia; Estradiol; Estrogen Replacement Therapy; Female; Humans; Menopause; Progestins | 2009 |
1 trial(s) available for dydrogesterone and Breast Cancer
| Article | Year |
|---|---|
Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Breast Neoplasms; Climacteric; Drug Therapy, Combination; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Insulin-Like Growth Factor I; Middle Aged; Norethindrone; Norethindrone Acetate; Risk Factors; Sex Hormone-Binding Globulin | 1994 |
9 other study(ies) available for dydrogesterone and Breast Cancer
| Article | Year |
|---|---|
Risk of breast cancer with HRT depends on therapy type and duration.
Topics: Age Factors; Aged; Breast Neoplasms; Case-Control Studies; Dydrogesterone; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Norethindrone; Progestins; Risk Factors; Time Factors | 2022 |
Progestogens and PGRMC1-dependent breast cancer tumor growth: An in-vitro and xenograft study.
Topics: Androstenes; Animals; Breast Neoplasms; Cell Proliferation; Cyproterone Acetate; Dydrogesterone; Estradiol; Female; Heterografts; Humans; In Vitro Techniques; MCF-7 Cells; Megestrol; Membrane Proteins; Mice; Mice, Nude; Nandrolone; Norethindrone; Progesterone; Progestins; Prospective Studies; Receptors, Progesterone | 2019 |
Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dydrogesterone; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Hormone Replacement Therapy; Humans; In Vitro Techniques; Norpregnenes; Progestins; Receptors, Estrogen; RNA, Messenger | 2008 |
Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations.
Topics: Adult; Aged; Breast Neoplasms; Case-Control Studies; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Odds Ratio; Ovarian Neoplasms; Risk Factors; Uterine Cervical Neoplasms; Uterine Neoplasms | 2009 |
The effect of continuous combined 17beta-oestradiol and dihydrodydrogesterone on apoptotic cell death and proliferation of human breast cancer cells in vitro.
Topics: 20-alpha-Dihydroprogesterone; Apoptosis; Breast Neoplasms; Cell Division; Drug Combinations; Dydrogesterone; Estradiol; Female; Humans; Tumor Cells, Cultured | 2002 |
In vitro effects of estradiol, dydrogesterone, tamoxifen and cyclophosphamide on proliferation vs. death in human breast cancer cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Death; Cell Division; Cell Nucleus; Cyclin D1; Cyclophosphamide; Dydrogesterone; Estradiol; Humans; Mucins; Progesterone Congeners; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Time Factors; Tumor Cells, Cultured | 2003 |
Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Contraceptive Agents, Female; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Humans; Medroxyprogesterone Acetate; Norethindrone; Norethindrone Acetate; Norpregnenes; Progesterone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured | 2005 |
Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.
Topics: Adult; Aged; Breast Neoplasms; Cohort Studies; Dydrogesterone; Estrogens; Female; Hormone Replacement Therapy; Humans; Middle Aged; Neoplasm Invasiveness; Postmenopause; Progesterone; Progestins; Risk | 2008 |
Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Dydrogesterone; Estrogens; Female; Humans; Middle Aged; Postmenopause; Progesterone; Progestins; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; SEER Program | 2008 |